Verastem VSTM
NASDAQ VSTM
$7.88 -0.11 (-1.32%)
As of: Sep 4, 2026 · 1:32 PM EDT

Verastem (VSTM) Non Operating Interest Expenses (2017 - 2026)

Analysis

Verastem (VSTM) Non Operating Interest Expenses (2017 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 139.27 Bn 131.42 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.55 Bn 77.56 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.45 Bn 58.27 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.73 Bn 52.59 Bn 52.00 Mn -
5 Revolution Medicines 44.08 Bn 44.08 Bn - 23.78 Mn
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.14 Bn 31.84 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - 93.62 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn 20.27 Mn
10 Verastem 788.41 Mn 652.06 Mn 36.32 Mn 360,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 360,000.00
Mar 31, 2026 382,000.00
Dec 31, 2025 415,000.00
Sep 30, 2025 319,000.00
Jun 30, 2025 212,000.00
Mar 31, 2025 192,000.00
Dec 31, 2024 1.15 Mn
Sep 30, 2024 1.15 Mn
Jun 30, 2024 1.14 Mn
Mar 31, 2024 1.13 Mn
Dec 31, 2023 1.12 Mn
Sep 30, 2023 1.13 Mn
Jun 30, 2023 1.12 Mn
Mar 31, 2023 769,000.00
Dec 31, 2022 724,000.00
Sep 30, 2022 717,000.00
Jun 30, 2022 640,000.00
Mar 31, 2022 56,000.00
Dec 31, 2021 10,000.00
Sep 30, 2021 7.98 Mn